Insightra Medical

Insightra Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Tennessee Medical Innovations Inc. (TNMI) is a private, commercial-stage medical device company headquartered in Clarksville, Tennessee. It serves as the US platform for the Mundomedis Group, following its acquisition in late 2021 and its subsequent acquisition of the assets of Insightra Medical in early 2022. The company is revenue-generating, marketing FDA-approved devices like intra-aortic balloon catheters and arthroscopy pumps to hospitals and ambulatory surgery centers globally. Its strategy leverages Mundomedis's resources to expand its innovative surgical device portfolio in the growing outpatient surgery market.

CardiovascularOrthopedics

Technology Platform

Applied product innovation in medical devices, particularly in miniaturization (7Fr IAB catheters) and automated surgical visualization (SmartVision fluid management). Serves as the US commercial and development platform for the Mundomedis Group.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Significant growth in the Ambulatory Surgery Center (ASC) segment, driven by the shift to outpatient procedures, presents a key opportunity for tailored, efficient devices.
The global demand for minimally invasive surgical tools and smaller-profile cardiovascular devices also aligns perfectly with TNMI's product portfolio and innovation focus.

Risk Factors

TNMI faces intense competition from large, established medical device companies and must successfully integrate acquired assets under its new corporate structure.
The company is also subject to regulatory hurdles and reimbursement pressures that can impact market adoption and profitability.

Competitive Landscape

The company competes in crowded markets dominated by giants like Getinge/MAQUET and Abbott in IABP, and Stryker, Arthrex, and Smith & Nephew in arthroscopy. TNMI's strategy is to differentiate through specific technological advantages (e.g., True 7Fr size, automated vision control) and a focused commercial approach on the ASC channel, which may be less prioritized by larger competitors.